echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > China Pharmaceutical Industry Association will hold a "feast of gluttony" in Chengdu in mid April

    China Pharmaceutical Industry Association will hold a "feast of gluttony" in Chengdu in mid April

    • Last Update: 2020-06-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    < br / > business news on April 2, notice on holding the 19th China Pharmaceutical Enterprise Marketing Summit Forum and the 5th chairman (enlarged) meeting of the 6th Association (baichuanhui Summit) < br / > < br / > < br / > < br / > < br / > all relevant units: < br / > < br / > < br / > < br / > < br / > 2011, It is the first year of the implementation of the 12th Five Year Plan, the final year of the recent key implementation plan of the medical and health system reform (2009-2011), the year of China's breakthrough in the key tasks and objectives of the medical reform in the past three years, and the key year of the effectiveness and influence of the new medical reform and its supporting policiesIn order to effectively promote the new medical reform and effectively implement the relevant policies, the State Council has made clear that all ministries and commissions work closely together to implement the new measures related to medical reform in a combined way< br / > < br / >, The 19th China Pharmaceutical Enterprise Marketing Summit Forum was held, and special activities such as the speech on the top 10 marketing cases of China Pharmaceutical in 2010 were organizedThe eight units of the brand summit are: < br / > < br / > < br / > < br / > < br / / > focus policy forum of medical reform: the new medical reform has entered the deep-water area, affecting the in-depth analysis of core industrial policies of pharmaceutical enterprises < br / > < br / > < br / > < br / > industry pattern prediction Forum: "under the background of industry upgrading in the 12th Five Year Plan, The strategy of medical power and the path choice of enterprise development, How can industry change channels to achieve win-win business strategy < br / > < br / > < br / > < br / / > share experience to win the future: 2010 Top Ten marketing case award ceremony of Chinese medicine, Sharing case release data < br / > < br / > < br / > < br / > < br / / > Forum on Anhui model advice: "two envelope" bidding (technical bid and commercial bid) system improvement and optimization forum < br / > < br / > < br / > < br / > < br / > responsibility · development · future: industry hot focus topic interaction Sharon, On the night of the 19th, "good doctor's night" wonderful sharing < br / > < br / > < br / > < br / / > game, joint effort and symbiosis: high-end dialogue of alliance or competition and business dockingOn the night of the 20th, "the night of Cologne" on Strategy < br / > < br / > < br / > < br / > < br / / > see Annex I for details of this meetingThe attending methods and precautions are as follows: < br / > < br / > < br / > < br / > < br / / > 1Meeting time: formal meeting on April 19-20, full day check-in on April 18Venue: Chengdu California Garden Hotel (No258, Shawan Road, Jinniu District, Chengdu; switchboard: 028-87649999) < br / > < br / > < br / > < br / / / > 2Participants: the chairman, general manager (president), deputy general manager (vice president), marketing director and other senior leaders of pharmaceutical industry and commerce enterprises; the heads of scientific research, education and investment institutions, Vice President (Executive Director) unit and member (director) unit of China Pharmaceutical Enterprise Management Association and China OTC Association< br / > < br / >All participants shall be responsible for their own transportation and accommodation expenses, and the meeting affairs group can assist in arrangingDue to the shortage of hotel accommodation due to the current drug fair, please help the hotel reservation representative to confirm before April 8< br / > < br / >< br / > < br / > < br / > < br / > Preferential measures: those who sign up and pay before April 8 can enjoy a 10% discount, and can get a set of proposal set of 2011 NPC and CPPCC medical representatives Forum jointly sponsored by 20 pharmaceutical industry associations during the two sessions of 2011; the deadline for signing up is April 15, and in principle, on-site registration is not acceptedAfter receiving the notice, each vice president (Executive Director), member (director) and contact person of relevant unit shall actively forward it to relevant person in charge, and select personnel to attend as soon as possibleThe electronic version of the application form can be found on the forum website http://Download, fill in carefully and print fax or email to the meeting affairs group< br / > : ccpervip@sina.comWebsite:or< br / > < br / > Company: Sichuan good doctor Pharmaceutical Group Co., LtdSichuan Kelun Pharmaceutical Co., Ltd< br / > < br / > < br / > Planning and Implementation: Caiyu Bank (Beijing) Management Consulting Co., Ltd., pharmaceutical manager magazine < br / > < br / > < br / > < br / > < br / / > supporting company: Sohu Health Channel, Senior Research Institute of State Food and drug administration, Kangzhi pharmaceutical industry < br / > < br / > < br / > < br / > < br / > main topics of the meeting < br / > < br / > < br / > < br / > < br / > Theme Forum 1: explore the "12th Five Year Plan" • pharmaceutical industry upgrading and enterprise path selection < br / > < br / > < br / > < br / > unit 1, focus industry policy forum: core industry policies and Background of the Forum: on February 13, 2011, the general office of the State Council released the main work arrangement of five key reforms of the medical and health system in 2011, making clear arrangements for 67 small points of work; on March 5, 2011, In his report on the work of the government at the fourth session of the Eleventh National People's Congress, Premier Wen Jiabao made it clear that this year is the crucial year for the implementation of the three-year plan for medical reformWe need to promote the reform and development of the medical and health sector and ensure that five objectives and tasks are completedIn addition, the new GMP (revised in 2010) has been implemented since March 1 this year, and the 12th Five Year Plan for the development of biomedical industry is also being developed under the leadership of the national development and Reform CommissionWhat kind of new impact will the new policies and measures have? The main topics of this unit are as follows: < br / > < br / > < br / > < br / > < br / / / > topic 1: the State Council's main work arrangement of 2011 medical reform and the five key reforms of the medical and health system to promote the effectiveness of evaluation and interpretation of the impact on the industry and opportunities for enterprises Article, improvement and optimization of the two envelope system, catalog adjustment, provincial supplement, implementation scope, bidding procurement) < br / > < br / > < br / > < br / > < br / / > topic 3: work arrangement of the State Council public hospital reform pilot in 2011, Analysis of industrial impact brought by new reform measures And the impact analysis of supporting implementation rules and the discussion of pharmaceutical enterprise certification guidelines and management countermeasures < br / > < br / > < br / > < br / / > topic 6: Voice of public hospitals and grass-roots hospitals, How to cooperate with the reform of public hospitals in pharmaceutical enterprises< Br / > the second unit, forum on industrial economic pattern: prospects of pharmaceutical industry pattern and opportunities and challenges for enterprise development under the national "12th Five Year Plan" < br / > < br / > < br / > < br / > Background: from 2006 to 2010, the total output value of China's pharmaceutical industry increased by 2.3 times, the profit increased by nearly 3 times, and the industrial development showed a rapid upward trendAt the same time of industrial scale expansion, China's drug production has changed from decentralization to intensificationFrom 2006 to 2009, the concentration of top 100 enterprises in the whole industry has increased from less than 40% to 42%, and there are 6 pharmaceutical enterprises with a scale of more than 8 billion yuanAccording to the report released by the national development and Reform Commission, in 2010, the production, sales and benefits of China's pharmaceutical industry continued to maintain a steady growth: the output value of the pharmaceutical industry reached 1123.9 billion yuan, a year-on-year growth of 26.4%; the total profit of the pharmaceutical industry reached 111.4 billion yuan (January November), a year-on-year growth of 28.3%; the export delivery value was 123.59 billion yuan, a year-on-year growth of 18.3%; the situation of foreign trade improved, Structural adjustment has been gradually promoted, and the industry as a whole has continued to improveOn this basis, the country is about to issue a series of "12th Five Year Plan" for the development of the pharmaceutical industryWhat is the development context and trend of China's pharmaceutical economy during the "12th Five Year Plan"? How should pharmaceutical enterprises see the trend and grasp the change? The main topics of this unit are as follows: < br / > < br / > < br / > < br / > topic 9: industrial impact, industrial pattern and enterprise opportunities under the 12th Five Year Plan of the pharmaceutical industry : analysis of the characteristics of China's pharmaceutical economy in 2011, interpretation of data and analysis of influencing factors in 2011, prediction of development trend < br / > < br / > < br / > < br / / > topic 12: Guidance on accelerating the structural adjustment of the pharmaceutical industry and the upgrading of the pharmaceutical industry and the transformation of pharmaceutical enterprises < br / > < br / > < br / > < br / / > topic 13: Top 100 pharmaceutical enterprises in the past five years Analysis on the trend of industry market concentration and perspective on its growth path Topic 16: Interpretation of China's pharmaceutical manufacturing industry safety assessment report and analysis of industry development warning significance
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.